Previous product
Back to products
Piqray (alpelisib)
CHF7,700.00
Next product
Balversa (erdafitinib)
CHF40,036.32
Rozlytrek (entrectinib)
CHF7,983.63
Rozlytrek (entrectinib) is a medication used for the treatment of NTRK-positive solid tumors, and ROS1-positive metastatic non-small cell lung cancer (NSCLC).
Reviews
There are no reviews yet.